H3K27 Methylation: A Focal Point of Epigenetic Deregulation in Cancer.

[1]  T. Perkins,et al.  UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemia , 2016, Genes & development.

[2]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[3]  T. Sixma,et al.  BAP1/ASXL1 recruitment and activation for H2A deubiquitination , 2016, Nature Communications.

[4]  Q. Li,et al.  Epigenetic regulation of gene expression by Ikaros, HDAC1 and Casein Kinase II in leukemia , 2015, Leukemia.

[5]  A. Italiano,et al.  Phase 1 Study of Tazemetostat (EPZ-6438), an Inhibitor of Enhancer of Zeste-Homolog 2 (EZH2): Preliminary Safety and Activity in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) Patients , 2015 .

[6]  Thomas P. Howard,et al.  SWI/SNF-mutant cancers depend on catalytic and non-catalytic activity of EZH2 , 2015, Nature Medicine.

[7]  S. Armstrong,et al.  The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79. , 2015, Molecular cell.

[8]  Simon Hallam,et al.  High Throughput Sequencing Analysis of the Immunoglobulin Heavy Chain Gene from Flow-Sorted B Cell Sub-Populations Define the Dynamics of Follicular Lymphoma Clonal Evolution , 2015, PloS one.

[9]  S. Armstrong,et al.  Loss of BAP1 function leads to EZH2-dependent transformation , 2015, Nature Medicine.

[10]  G. Kong,et al.  UTX inhibits EMT‐induced breast CSC properties by epigenetic repression of EMT genes in cooperation with LSD1 and HDAC1 , 2015, EMBO reports.

[11]  H. Lähdesmäki,et al.  Cancer-associated ASXL1 mutations may act as gain-of-function mutations of the ASXL1–BAP1 complex , 2015, Nature Communications.

[12]  Joshua M. Korn,et al.  Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors , 2015, Oncogene.

[13]  J. Kench,et al.  Whole genomes redefine the mutational landscape of pancreatic cancer , 2015, Nature.

[14]  V. Stojanoff,et al.  Small-molecule modulators of methyl-lysine binding for the CBX7 chromodomain. , 2015, Chemistry & biology.

[15]  Y. Xiong,et al.  WT1 recruits TET2 to regulate its target gene expression and suppress leukemia cell proliferation. , 2015, Molecular cell.

[16]  Benjamin G. Bitler,et al.  Synthetic lethality by targeting EZH2 methyltransferase activity in ARID1A-mutated cancers , 2015, Nature Medicine.

[17]  Zheng Zhou,et al.  Strong expression of EZH2 and accumulation of trimethylated H3K27 in diffuse large B-cell lymphoma independent of cell of origin and EZH2 codon 641 mutation , 2015, Leukemia & lymphoma.

[18]  M. Follettie,et al.  Epigenetic reprogramming by tumor-derived EZH2 gain-of-function mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth , 2015, Oncotarget.

[19]  R. Dummer,et al.  The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors , 2015, Nature Communications.

[20]  A. Feinberg,et al.  Mutant WT1 is associated with DNA hypermethylation of PRC2 targets in AML and responds to EZH2 inhibition. , 2015, Blood.

[21]  C. Allis,et al.  Use of human embryonic stem cells to model pediatric gliomas with H3.3K27M histone mutation , 2014, Science.

[22]  S. Armstrong,et al.  AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes. , 2014, Cancer cell.

[23]  B. Garcia,et al.  Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. , 2014, Blood.

[24]  G. Tonon,et al.  Loss of the Histone Demethylase UTX Contributes to Multiple Myeloma and Sensitizes Cells to EZH2 Inhibitors , 2014 .

[25]  E. Pronier,et al.  DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. , 2014, Cell reports.

[26]  C. Plass,et al.  PRC2 loss amplifies Ras signaling in cancer , 2014, Nature Genetics.

[27]  Claude Gazin,et al.  TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein , 2014, Nature.

[28]  L. Qin,et al.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors , 2014, Nature Genetics.

[29]  Zhiming Cai,et al.  Concurrent Alterations in TERT, KDM6A, and the BRCA Pathway in Bladder Cancer , 2014, Clinical Cancer Research.

[30]  C. James,et al.  Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma , 2014, Nature Medicine.

[31]  Eugenia G. Giannopoulou,et al.  Histone Methyltransferase MMSET/NSD2 Alters EZH2 Binding and Reprograms the Myeloma Epigenome through Global and Focal Changes in H3K36 and H3K27 Methylation , 2014, PLoS genetics.

[32]  R. Johnstone,et al.  Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders , 2014, Nature Reviews Drug Discovery.

[33]  Kyle V. Butler,et al.  Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8 , 2014, Journal of medicinal chemistry.

[34]  R. Jaenisch,et al.  Contrasting roles for histone 3 lysine 27 demethylases in acute lymphoblastic leukemia , 2014, Nature.

[35]  A. Iwama,et al.  Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation , 2014, Nature Communications.

[36]  N. Brockdorff,et al.  Variant PRC1 Complex-Dependent H2A Ubiquitylation Drives PRC2 Recruitment and Polycomb Domain Formation , 2014, Cell.

[37]  A. Fusco,et al.  CBX7 Modulates the Expression of Genes Critical for Cancer Progression , 2014, PloS one.

[38]  M. Vermeulen,et al.  Histone H2A monoubiquitination promotes histone H3 methylation in Polycomb repression , 2014, Nature Structural &Molecular Biology.

[39]  Liliana Goumnerova,et al.  Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma , 2014, Nature Genetics.

[40]  Min Gyu Lee,et al.  UTX and MLL4 coordinately regulate transcriptional programs for cell proliferation and invasiveness in breast cancer cells. , 2014, Cancer research.

[41]  Michael Brudno,et al.  Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations , 2014, Nature Genetics.

[42]  Tim J. Wigle,et al.  Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma , 2014, Molecular Cancer Therapeutics.

[43]  A. Singh,et al.  EZH2: Not EZHY (Easy) to Deal , 2014, Molecular Cancer Research.

[44]  Fang Fang,et al.  The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. , 2014, Blood.

[45]  S. Gabriel,et al.  Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.

[46]  David T. W. Jones,et al.  Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. , 2013, Cancer cell.

[47]  H. Aburatani,et al.  Myelodysplastic syndromes are induced by histone methylation–altering ASXL1 mutations. , 2013, The Journal of clinical investigation.

[48]  M. Stratton,et al.  Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone , 2013, Nature Genetics.

[49]  Manel Juan,et al.  Landscape of somatic mutations and clonal evolution in mantle cell lymphoma , 2013, Proceedings of the National Academy of Sciences.

[50]  Huanming Yang,et al.  Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation , 2013, Nature Genetics.

[51]  Jacob D. Jaffe,et al.  Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia , 2013, Nature Genetics.

[52]  M. Ramalho-Santos,et al.  Histone variant H3.3 maintains a decondensed chromatin state essential for mouse preimplantation development , 2013, Development.

[53]  S. Orkin,et al.  Targeted Disruption of the EZH2/EED Complex Inhibits EZH2-dependent Cancer , 2013, Nature chemical biology.

[54]  X. Hua,et al.  Menin: a scaffold protein that controls gene expression and cell signaling. , 2013, Trends in biochemical sciences.

[55]  D. Nam,et al.  Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. , 2013, Cancer cell.

[56]  A. Jankowska,et al.  Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies , 2013, Leukemia.

[57]  Qiang Yu,et al.  EZH2 overexpression in natural killer /T-cell lymphoma confers growth advantage independently of histone methyltransferase activity , 2013 .

[58]  Benjamin J. Raphael,et al.  The Mutational Landscape of Adenoid Cystic Carcinoma , 2013, Nature Genetics.

[59]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[60]  O. Elemento,et al.  EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. , 2013, Cancer cell.

[61]  Sabine Mueller,et al.  The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.

[62]  P. Cairns,et al.  Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC , 2013, Epigenetics.

[63]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[64]  A. Sun,et al.  EZH2 Mutations Are Related to Low Blast Percentage in Bone Marrow and -7/del(7q) in De Novo Acute Myeloid Leukemia , 2013, PloS one.

[65]  P. Knoepfler,et al.  Endogenous mammalian histone H3.3 exhibits chromatin-related functions during development , 2013, Epigenetics & Chromatin.

[66]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[67]  O. Elemento,et al.  MMSET dysregulates gene expression in myeloma through global and focal changes in H3K36 and H3K27 methylation , 2013, Epigenetics & Chromatin.

[68]  K. Helin,et al.  Polycomb Cbx family members mediate the balance between haematopoietic stem cell self-renewal and differentiation , 2013, Nature Cell Biology.

[69]  S. Lowe,et al.  The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia , 2013, Oncogene.

[70]  M. Esteller,et al.  Genetic syndromes caused by mutations in epigenetic genes , 2013, Human Genetics.

[71]  Zhaohui S. Qin,et al.  Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer. , 2013, Molecular cell.

[72]  M. Loda,et al.  EZH2 Oncogenic Activity in Castration-Resistant Prostate Cancer Cells Is Polycomb-Independent , 2012, Science.

[73]  T. Veenstra,et al.  Histone Demethylase Jumonji D3 (JMJD3) as a Tumor Suppressor by Regulating p53 Protein Nuclear Stabilization , 2012, PloS one.

[74]  S. Ogawa,et al.  EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms , 2012, Leukemia.

[75]  A. Emili,et al.  Discovery of a chemical probe for the L3MBTL3 methyl-lysine reader domain , 2012, Nature chemical biology.

[76]  M. Hazar-Rethinam,et al.  Dysregulation of the Repressive H3K27 Trimethylation Mark in Head and Neck Squamous Cell Carcinoma Contributes to Dysregulated Squamous Differentiation , 2012, Clinical Cancer Research.

[77]  David T. W. Jones,et al.  Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.

[78]  Lei Jin,et al.  A687V EZH2 is a gain‐of‐function mutation found in lymphoma patients , 2012, FEBS letters.

[79]  Somasekar Seshagiri,et al.  Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation , 2012, Science.

[80]  Stefano Monti,et al.  Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. , 2012, Cancer cell.

[81]  X. Zhou,et al.  Dense Chromatin Activates Polycomb Repressive Complex 2 to Regulate H3 Lysine 27 Methylation , 2012, Science.

[82]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[83]  Jonathan D. Licht,et al.  Total kinetic analysis reveals how combinatorial methylation patterns are established on lysines 27 and 36 of histone H3 , 2012, Proceedings of the National Academy of Sciences.

[84]  S. Sugano,et al.  Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.

[85]  Christopher J. Schofield,et al.  A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response , 2012, Nature.

[86]  A. Sivachenko,et al.  A Landscape of Driver Mutations in Melanoma , 2012, Cell.

[87]  N. Kelleher,et al.  The Histone Methyltransferase MMSET/WHSC1 Activates TWIST1 to Promote an Epithelial-Mesenchymal Transition and Invasive Properties of Prostate Cancer , 2012, Oncogene.

[88]  David T. W. Jones,et al.  K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas , 2012, Acta Neuropathologica.

[89]  Christoph Bock,et al.  Sequential ChIP-bisulfite sequencing enables direct genome-scale investigation of chromatin and DNA methylation cross-talk , 2012, Genome research.

[90]  M. Robinson,et al.  Bisulfite sequencing of chromatin immunoprecipitated DNA (BisChIP-seq) directly informs methylation status of histone-modified DNA , 2012, Genome research.

[91]  N. Grishin,et al.  BAP1 loss defines a new class of renal cell carcinoma , 2012, Nature Genetics.

[92]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[93]  P. Scacheri,et al.  Histone Demethylase UTX and Chromatin Remodeler BRM Bind Directly to CBP and Modulate Acetylation of Histone H3 Lysine 27 , 2012, Molecular and Cellular Biology.

[94]  Jindan Yu,et al.  Interrogating genomic and epigenomic data to understand prostate cancer. , 2012, Biochimica et biophysica acta.

[95]  G. Boucher,et al.  A key role for EZH2 and associated genes in mouse and human adult T-cell acute leukemia. , 2012, Genes & development.

[96]  Shadan Ali,et al.  Loss of Let-7 Up-Regulates EZH2 in Prostate Cancer Consistent with the Acquisition of Cancer Stem Cell Signatures That Are Attenuated by BR-DIM , 2012, PloS one.

[97]  S. Armstrong,et al.  Polycomb repressive complex 2 is required for MLL-AF9 leukemia , 2012, Proceedings of the National Academy of Sciences.

[98]  Yong Jiang,et al.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.

[99]  David T. W. Jones,et al.  Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma , 2012, Nature.

[100]  S. Scherer,et al.  Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.

[101]  Li Ding,et al.  Somatic Histone H3 Alterations in Paediatric Diffuse Intrinsic Pontine Gliomas and Non-Brainstem Glioblastomas , 2012, Nature Genetics.

[102]  Kiran C. Bobba,et al.  The genetic basis of early T-cell precursor acute lymphoblastic leukaemia , 2012, Nature.

[103]  Giacomo Cavalli,et al.  Trithorax group proteins: switching genes on and keeping them active , 2011, Nature Reviews Molecular Cell Biology.

[104]  B. Garcia,et al.  NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. , 2011, Molecular cell.

[105]  Jing Liang,et al.  Corepressor Protein CDYL Functions as a Molecular Bridge between Polycomb Repressor Complex 2 and Repressive Chromatin Mark Trimethylated Histone Lysine 27* , 2011, The Journal of Biological Chemistry.

[106]  Kwok-Kin Wong,et al.  Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. , 2011, Cancer cell.

[107]  Huanming Yang,et al.  Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder , 2011, Nature Genetics.

[108]  N. Cox,et al.  Germline BAP1 mutations predispose to malignant mesothelioma , 2011, Nature Genetics.

[109]  D. Birnbaum,et al.  Mutations and deletions of the SUZ12 polycomb gene in myeloproliferative neoplasms , 2011, Blood cancer journal.

[110]  Jeannie T. Lee,et al.  YY1 Tethers Xist RNA to the Inactive X Nucleation Center , 2011, Cell.

[111]  A. McKenna,et al.  The Mutational Landscape of Head and Neck Squamous Cell Carcinoma , 2011, Science.

[112]  Xiao Li,et al.  Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: relation to adverse epigenetic alteration and poor prognostic scoring , 2011, Annals of Hematology.

[113]  P. Angrand,et al.  Functional characterization of human Polycomb-like 3 isoforms identifies them as components of distinct EZH2 protein complexes. , 2011, The Biochemical journal.

[114]  M. Salto‐Tellez,et al.  Activated oncogenic pathways and therapeutic targets in extranodal nasal‐type NK/T cell lymphoma revealed by gene expression profiling , 2011, The Journal of pathology.

[115]  Ryan D. Morin,et al.  Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. , 2011, Blood.

[116]  Paul Tempst,et al.  PRC2 Complexes with JARID2, MTF2, and esPRC2p48 in ES Cells to Modulate ES Cell Pluripotency and Somatic Cell Reprograming , 2011, Stem cells.

[117]  G. Almouzni,et al.  The double face of the histone variant H3.3 , 2011, Cell Research.

[118]  B. Zhu,et al.  H3K36 Methylation Antagonizes PRC2-mediated H3K27 Methylation* , 2011, The Journal of Biological Chemistry.

[119]  L. Staudt,et al.  The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. , 2011, Blood.

[120]  Toshiro K. Ohsumi,et al.  Genome-wide identification of polycomb-associated RNAs by RIP-seq. , 2010, Molecular cell.

[121]  Raul Rabadan,et al.  Inactivating mutations of acetyltransferase genes in B-cell lymphoma , 2010, Nature.

[122]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[123]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[124]  B. Bernstein,et al.  Mammalian Polycomb-Like Pcl2/Mtf2 Is a Novel Regulatory Component of PRC2 That Can Differentially Modulate Polycomb Activity both at the Hox Gene Cluster and at Cdkn2a Genes , 2010, Molecular and Cellular Biology.

[125]  Chao Xu,et al.  Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2) , 2010, Proceedings of the National Academy of Sciences.

[126]  Scott L Pomeroy,et al.  Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. , 2010, Cancer cell.

[127]  E. Kremmer,et al.  Identification and characterization of two novel primate-specific histone H3 variants, H3.X and H3.Y , 2010, The Journal of cell biology.

[128]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[129]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[130]  C. Allis,et al.  Daxx is an H3.3-specific histone chaperone and cooperates with ATRX in replication-independent chromatin assembly at telomeres , 2010, Proceedings of the National Academy of Sciences.

[131]  E. Delbarre,et al.  Chromatin Environment of Histone Variant H3.3 Revealed by Quantitative Imaging and Genome-scale Chromatin and DNA Immunoprecipitation , 2010, Molecular biology of the cell.

[132]  G. Kristiansen,et al.  Class I histone deacetylases 1, 2 and 3 are highly expressed in classical Hodgkin's lymphoma , 2010, Expert opinion on therapeutic targets.

[133]  A. Fusco,et al.  Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. , 2010, European journal of cancer.

[134]  Kristian Helin,et al.  Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes , 2010, Nucleic acids research.

[135]  Juri Rappsilber,et al.  JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells , 2010, Nature.

[136]  S. Rafii,et al.  Distinct Factors Control Histone Variant H3.3 Localization at Specific Genomic Regions , 2010, Cell.

[137]  Nevan J Krogan,et al.  Polycomb-like 2 associates with PRC2 and regulates transcriptional networks during mouse embryonic stem cell self-renewal and differentiation. , 2010, Cell stem cell.

[138]  Gang Li,et al.  Jarid2 and PRC2, partners in regulating gene expression. , 2010, Genes & development.

[139]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[140]  Arend Sidow,et al.  Jarid2/Jumonji Coordinates Control of PRC2 Enzymatic Activity and Target Gene Occupancy in Pluripotent Cells , 2009, Cell.

[141]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[142]  P. Scacheri,et al.  CBP-mediated acetylation of histone H3 lysine 27 antagonizes Drosophila Polycomb silencing , 2009, Development.

[143]  Y. Furukawa,et al.  Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic Progenitors* , 2009, The Journal of Biological Chemistry.

[144]  Vincenza Leone,et al.  Chromobox protein homologue 7 protein, with decreased expression in human carcinomas, positively regulates E-cadherin expression by interacting with the histone deacetylase 2 protein. , 2009, Cancer research.

[145]  Dinshaw J. Patel,et al.  Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD finger , 2009, Nature.

[146]  G. Neri,et al.  Faculty Opinions recommendation of Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. , 2009 .

[147]  G. Morgan,et al.  MMSET deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells , 2009, Haematologica.

[148]  S. Varambally,et al.  Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer , 2008, Science.

[149]  S. Dhanasekaran,et al.  Repression of E-cadherin by the polycomb group protein EZH2 in cancer , 2008, Oncogene.

[150]  S. Elledge,et al.  CDYL bridges REST and histone methyltransferases for gene repression and suppression of cellular transformation. , 2008, Molecular cell.

[151]  D. Reinberg,et al.  Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. , 2008, Molecular cell.

[152]  I. Christensen,et al.  Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma , 2008, Histopathology.

[153]  P. Hokland,et al.  Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia , 2008, European journal of haematology.

[154]  Y. Nakanuma,et al.  Over‐expression of polycomb group protein EZH2 relates to decreased expression of p16INK4a in cholangiocarcinogenesis in hepatolithiasis , 2008, The Journal of pathology.

[155]  Terry Magnuson,et al.  Polycomb Repressive Complex 2 Is Dispensable for Maintenance of Embryonic Stem Cell Pluripotency , 2008, Stem cells.

[156]  C. Verrijzer,et al.  SWI/SNF Mediates Polycomb Eviction and Epigenetic Reprogramming of the INK4b-ARF-INK4a Locus , 2008, Molecular and Cellular Biology.

[157]  R. Arceci,et al.  The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. , 2008, Blood.

[158]  T. Veenstra,et al.  Identification of JmjC domain-containing UTX and JMJD3 as histone H3 lysine 27 demethylases , 2007, Proceedings of the National Academy of Sciences.

[159]  Min Gyu Lee,et al.  Demethylation of H3K27 Regulates Polycomb Recruitment and H2A Ubiquitination , 2007, Science.

[160]  J. Chai,et al.  Structural basis of EZH2 recognition by EED. , 2007, Structure.

[161]  I. Issaeva,et al.  UTX and JMJD3 are histone H3K27 demethylases involved in HOX gene regulation and development , 2007, Nature.

[162]  H. Stunnenberg,et al.  Pcl-PRC2 is needed to generate high levels of H3-K27 trimethylation at Polycomb target genes , 2007, The EMBO journal.

[163]  G. Dressler,et al.  PTIP Associates with MLL3- and MLL4-containing Histone H3 Lysine 4 Methyltransferase Complex*♦ , 2007, Journal of Biological Chemistry.

[164]  G. Wang,et al.  NUP98–NSD1 links H3K36 methylation to Hox-A gene activation and leukaemogenesis , 2007, Nature Cell Biology.

[165]  Qiang Yu,et al.  Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. , 2007, Genes & development.

[166]  Kristian Helin,et al.  The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation , 2007, Molecular and Cellular Biology.

[167]  T. Kouzarides.  Chromatin Modifications and Their Function , 2007, Cell.

[168]  C. Croce,et al.  Knockdown of ALR (MLL2) Reveals ALR Target Genes and Leads to Alterations in Cell Adhesion and Growth , 2006, Molecular and Cellular Biology.

[169]  A. Chinnaiyan,et al.  Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells , 2006, Molecular Cancer Therapeutics.

[170]  Tapio Visakorpi,et al.  The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late‐stage prostate cancer , 2006, Genes, chromosomes & cancer.

[171]  L. Bystrykh,et al.  The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. , 2006, Blood.

[172]  O. Halvorsen,et al.  EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[173]  Hiroko Yamashita,et al.  Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast* , 2005, Breast Cancer Research and Treatment.

[174]  Matthew Meyerson,et al.  The Menin Tumor Suppressor Protein Is an Essential Oncogenic Cofactor for MLL-Associated Leukemogenesis , 2005, Cell.

[175]  J. Keats,et al.  Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. , 2005, Blood.

[176]  Kristian Helin,et al.  Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity , 2004, The EMBO journal.

[177]  Yi Zhang,et al.  The functions of E(Z)/EZH2-mediated methylation of lysine 27 in histone H3. , 2004, Current opinion in genetics & development.

[178]  Kristian Helin,et al.  EZH2 is downstream of the pRB‐E2F pathway, essential for proliferation and amplified in cancer , 2003, The EMBO journal.

[179]  Debashis Ghosh,et al.  EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[180]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[181]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[182]  Brigitte Wild,et al.  Histone Methyltransferase Activity of a Drosophila Polycomb Group Repressor Complex , 2002, Cell.

[183]  V. Pirrotta,et al.  Drosophila Enhancer of Zeste/ESC Complexes Have a Histone H3 Methyltransferase Activity that Marks Chromosomal Polycomb Sites , 2002, Cell.

[184]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[185]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[186]  S. Henikoff,et al.  The histone variant H3.3 marks active chromatin by replication-independent nucleosome assembly. , 2002, Molecular cell.

[187]  M. Lipinski,et al.  HIRA is critical for a nucleosome assembly pathway independent of DNA synthesis. , 2002, Molecular cell.

[188]  E. Lander,et al.  Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. , 2002, Cancer cell.

[189]  H. Kwon,et al.  Expression Profile of Histone Deacetylase 1 in Gastric Cancer Tissues , 2001, Japanese journal of cancer research : Gann.

[190]  A. Otte,et al.  Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation , 1999, Nature Genetics.

[191]  K. Bomsztyk,et al.  Point Mutations in the WD40 Domain of Eed Block Its Interaction with Ezh2 , 1998, Molecular and Cellular Biology.

[192]  O. Witt,et al.  Testis-specific expression of a novel human H3 histone gene. , 1996, Experimental cell research.

[193]  R. I. Glazer,et al.  3-Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine hydrolase and its effects on human promyelocytic leukemia cell line HL-60. , 1986, Biochemical and biophysical research communications.

[194]  E. Rego,et al.  Overexpression of EZH2 associates with a poor prognosis in chronic lymphocytic leukemia. , 2015, Blood cells, molecules & diseases.

[195]  N. Kelleher,et al.  Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies , 2014, Leukemia.

[196]  J. Khan,et al.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.

[197]  K. Döhner,et al.  Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. , 2012, Blood.

[198]  A. Fusco,et al.  CBX7 is a tumor suppressor in mice and humans. , 2012, The Journal of clinical investigation.

[199]  Hana Kim,et al.  AEBP2 as a potential targeting protein for Polycomb Repression Complex PRC2 , 2009 .

[200]  Peter A. Jones,et al.  The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. , 2009, Cancer research.

[201]  L. J,et al.  Rearrangement of the MLL Gene Confers a Poor Prognosis in Childhood Acute Lymphoblastic Leukemia , Regardless of Presenting Age , 2002 .